Leerink Partnrs Comments on Myriad Genetics Q2 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN) – Research analysts at Leerink Partnrs issued their Q2 2026 earnings estimates for shares of Myriad Genetics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst P. Souda forecasts that the company will earn ($0.02) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.02 EPS.

Other analysts have also issued reports about the company. Bank of America dropped their target price on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a report on Friday, December 13th. StockNews.com cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Saturday. Craig Hallum assumed coverage on shares of Myriad Genetics in a report on Wednesday, February 12th. They set a “buy” rating and a $29.00 target price for the company. Stephens reissued an “equal weight” rating and set a $20.00 price target on shares of Myriad Genetics in a report on Thursday, January 16th. Finally, Leerink Partners cut shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $30.00 to $21.00 in a report on Monday, December 9th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $22.14.

Myriad Genetics Price Performance

Shares of MYGN opened at $10.73 on Thursday. The business’s 50-day moving average is $13.28 and its two-hundred day moving average is $19.04. The company has a market capitalization of $976.81 million, a P/E ratio of -8.25 and a beta of 1.88. Myriad Genetics has a fifty-two week low of $9.76 and a fifty-two week high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The business had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same quarter in the previous year, the company earned ($0.12) EPS.

Institutional Investors Weigh In On Myriad Genetics

Several institutional investors have recently bought and sold shares of MYGN. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Myriad Genetics by 43.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 285,229 shares of the company’s stock valued at $3,910,000 after acquiring an additional 86,973 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in Myriad Genetics in the 4th quarter valued at $1,635,000. Squarepoint Ops LLC lifted its holdings in Myriad Genetics by 27.0% in the 4th quarter. Squarepoint Ops LLC now owns 138,869 shares of the company’s stock valued at $1,904,000 after purchasing an additional 29,524 shares in the last quarter. Twinbeech Capital LP acquired a new stake in Myriad Genetics during the 4th quarter worth $562,000. Finally, Rafferty Asset Management LLC grew its holdings in shares of Myriad Genetics by 50.4% during the fourth quarter. Rafferty Asset Management LLC now owns 166,138 shares of the company’s stock worth $2,278,000 after buying an additional 55,690 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.